Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Blood Test Detects Organ Rejection in Heart Transplant Patients

By LabMedica International staff writers
Posted on 30 Jun 2025

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. More...

Rejection happens when the recipient’s immune system identifies the transplanted heart as foreign and launches an immune response against it. The most frequent form of rejection is acute cellular rejection, which involves immune cells known as T cells. This condition is categorized into mild, moderate, or severe grades. Mild rejection usually doesn’t show symptoms, though some patients might experience vague, flu-like signs.

In more serious cases, symptoms can include an irregular or rapid heartbeat, low blood pressure, dizziness, and difficulty breathing. Through tissue biopsies, pathologists can detect rejection by examining the presence of T cells and evaluating the level of damage they inflict on the transplanted heart. The assigned grade informs the appropriate course of treatment. In cases of moderate or severe rejection found via biopsy, doctors typically increase immunosuppressive medication to reverse it, whereas mild rejection is often just monitored. However, there is currently no reliable, noninvasive method to verify whether treatment is effective.

Since therapies differ for acute cellular rejection and antibody-mediated rejection, a diagnostic test capable of detecting and distinguishing between these types would be invaluable for guiding treatment decisions. Conducting heart biopsies carries risks, prompting researchers over the years to search for alternative biomarkers that could replace invasive procedures. Most episodes of acute cellular rejection occur within the first six months post-transplant. Unfortunately, the limited blood tests available today are not effective at identifying rejection during the crucial initial 30 days. A less invasive method to monitor immune activity would be transformative for transplant recipients. Researchers now point to a promising biomarker that could make it possible to replace surgical biopsies with a simple blood test.

Over the past decade, scientists at the Yale School of Medicine (YSM, New Haven, CT, USA) have been investigating exosomes as a potential biomarker for heart transplant rejection in animal studies. Cells use exosomes—tiny biological packages filled with molecules—to communicate and transfer information. A new study published in the journal Transplantation marks a major step in translating this research from animal models to human heart transplant patients, potentially introducing biomarker testing into clinical practice. In this study, blood samples were collected from 12 heart transplant patients before and after surgery, and researchers analyzed the molecular contents of exosomes released by T cells, B cells, and the transplanted donor heart. Six patients experienced a total of 11 episodes of moderate acute cellular rejection. When the heart was not being attacked by T cells, the team observed specific patterns of molecular content in the exosomes from the heart and T cells. However, when rejection occurred, they detected increased levels of markers linked to the rejection process.

Importantly, one patient experienced a different type of rejection known as antibody-mediated rejection, which primarily involves B cells, aided by T cells. By analyzing the exosomes from that patient’s B cells, researchers were also able to detect this form of rejection. Of the 11 total rejection episodes recorded in the study, 10 occurred within the first 38 days after transplant, and researchers successfully identified all of them. When patients received treatment for rejection, the molecular signatures in exosomes from T cells and donor heart cells shifted back toward their baseline levels. The team at YSM is now expanding their research by analyzing biopsy samples from more than 100 patients. With this larger group, they aim to further evaluate their platform’s effectiveness in detecting different types of rejection, including antibody-mediated cases.

“Not only can we detect rejection, but our investigation also suggests that we can use our exosome platform to potentially monitor the efficacy of treatment of rejection,” said principal investigator Prashanth Vallabhajosyula, MD, who led the research team.

“This is the first time that we’ve had a noninvasive method to delineate between the different types of rejection that may occur within the heart,” added study co-author Sounok Sen, MD.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.